Academic clinical trial

PA Options for Wellness' Medical Retail Presence Grows to Six 'Vytal Options' Dispensary Locations in Pennsylvania

Retrieved on: 
Sunday, September 4, 2022

HARRISBURG, Pa., Sept. 04, 2022 (GLOBE NEWSWIRE) -- PA Options for Wellness ("PA Options for Wellness", DBA "Vytal Options" or the "Company"), a leading provider of consumer products in the Pennsylvania medical cannabis market, announced today the opening of two new medical marijuana dispensaries, bringing their retail footprint to a total of six locations throughout Pennsylvania.

Key Points: 
  • HARRISBURG, Pa., Sept. 04, 2022 (GLOBE NEWSWIRE) -- PA Options for Wellness ("PA Options for Wellness", DBA "Vytal Options" or the "Company"), a leading provider of consumer products in the Pennsylvania medical cannabis market, announced today the opening of two new medical marijuana dispensaries, bringing their retail footprint to a total of six locations throughout Pennsylvania.
  • "We were one of the first three medical marijuana Clinical Registrants approved by the Pennsylvania Department of Health to conduct research.
  • In addition to PA Options for Wellness' newest dispensary locations, the Company currently serves patients inthe following areas: Harrisburg, Lancaster, Lansdale, and the Lehigh Valley.
  • PA Options for Wellness will bring top-quality, innovative products to the medical market, meeting the demand of our patients while adhering to strict ethical standards.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

When It All Works: Case Studies for Success With Patient Diversity in Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, January 27, 2021

How can early development of sound clinical and ethical expectations for a clinical trial drive better outcomes?

Key Points: 
  • How can early development of sound clinical and ethical expectations for a clinical trial drive better outcomes?
  • What difference does it make to apply business intelligence and analytics to the challenges of diversity?
  • Join this discussion with industry experts to learn how clinical trial Sponsors, study sites, and other support teams have made this work.
  • For more information, or to register for this event, visit When It All Works: Case Studies for Success With Patient Diversity in Clinical Trials .

Medable Launches TeleConsent for Clinical Trials, Dramatically Improving Patient Access and Experience

Retrieved on: 
Tuesday, September 22, 2020

Medable TeleConsent solves one of the most complex aspects of clinical trials for sites and sponsorsand transforms the initial experience for patients.

Key Points: 
  • Medable TeleConsent solves one of the most complex aspects of clinical trials for sites and sponsorsand transforms the initial experience for patients.
  • By eliminating the need for multiple round-trip visits to clinical sites, TeleConsent dramatically improves patient access to studies, connecting them directly with trial investigators and site teams from their home location.
  • Medable TeleConsent was designed uniquely with a patient-centric perspective, informed by Medables Patient Advisory Council , a nationwide network of advocates who advise Medable and customers on ways to improve patient access, experience, and outcomes.
  • Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes.

The Conference Forum Announces Mobile in Clinical Trials Conference Goes Virtual and Addresses Urgent Adoption of Digital Solutions for Clinical Research

Retrieved on: 
Wednesday, June 3, 2020

This annual conference challenges biopharma R&D on how to embrace, adapt and scale mobile and digital technologies to reduce the barriers for patients and physicians to participate in clinical research.

Key Points: 
  • This annual conference challenges biopharma R&D on how to embrace, adapt and scale mobile and digital technologies to reduce the barriers for patients and physicians to participate in clinical research.
  • "As COVID-19 has disrupted so many clinical trials, the need for remote digital solutions has never been more urgent."
  • Mobile in Clinical Trials features industry-led examples of how clinical trials can be more flexible for patients and physicians and will be presented in a virtual format to accommodate clinical researchers, patient advocates and technologists.
  • The Conference Forum is a life science industry research firm that develops conferences primarily around getting therapeutics to patients faster.

Synteract Leverages the TriNetX Platform and COVID-19 Rapid Response Network to Find and Enroll Patients for Coronavirus Clinical Trials

Retrieved on: 
Thursday, April 23, 2020

Since launching, seven clinical trials involving treatments and vaccines have been presented to HCOs within the network.

Key Points: 
  • Since launching, seven clinical trials involving treatments and vaccines have been presented to HCOs within the network.
  • Trial Connect, a key feature of the TriNetX platform, enables the pharmaceutical community to efficiently and directly engage clinical trial offices at HCOs with potential trial opportunities for COVID-19 patients.
  • "As the pandemic spreads, time is of the essence as we try to contain it," said Jennifer Stacey, Vice President, Clinical Sciences at TriNetX.
  • "Being able to provide access to up-to-date COVID-19 clinical data to researchers quickly is crucial since the world is depending on clinical trials to find ways to treat this disease.

Care Access Research Launches COVID-19 Clinical Trials Alliance to Accelerate Vaccine and Drug Development

Retrieved on: 
Friday, April 10, 2020

BOSTON, April 9, 2020 /PRNewswire/ -- Care Access Research , the leader in rapid development and management of high-performing clinical research sites, announced it launched the COVID-19 Clinical Trials Alliance to connect sites, sponsors and CROs to accelerate COVID-19 trials required for FDA approval of vaccines, drugs and diagnostics.

Key Points: 
  • BOSTON, April 9, 2020 /PRNewswire/ -- Care Access Research , the leader in rapid development and management of high-performing clinical research sites, announced it launched the COVID-19 Clinical Trials Alliance to connect sites, sponsors and CROs to accelerate COVID-19 trials required for FDA approval of vaccines, drugs and diagnostics.
  • Anticipating the urgent need for speeding up the clinical trial process, Care Access Research started the COVID-19 Clinical Trials Alliance to help solve the health care industry's next challenge: quickly finding enough sites capable of running efficient, high-quality COVID-19 trials.
  • The COVID-19 Clinical Trials Alliance will accelerate trials by matching research-enabled sites with study sponsors.
  • By uniting healthcare heroes to bridge standard care with clinical research, Care Access Research is transforming the industry to accelerate the development of breakthrough therapies and life-saving treatments.

Global Coronavirus COVID 19 Clinical Trials Insight 2020

Retrieved on: 
Wednesday, April 1, 2020

Number Of Drugs In Clinical Trials: >30 Drugs

Key Points: 
  • Number Of Drugs In Clinical Trials: >30 Drugs
    Majority Of Drugs in Research Phase: > 15 Drugs
    USA & China Dominating Clinical Trials: >20 Drugs
    Vaccines Accounts Major Share In Clinical Trials: >10 Vaccines
    The research report "Global Coronavirus COVID 19 Clinical Trials Insight 2020" discusses about the recent outbreak of coronavirus that has badly affected the human life globally.
  • The report provides an in-depth analysis about the clinical trials of drugs and therapies for the virus that is going to be covered in the next few years.
  • In general the report has been prepared with a view of providing all the clinical parameters associated with the virus therapy research.
  • On an average, more than 30 clinical trials are getting conducted at the global level, with hundreds of patients enrolled in it.

Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, March 24, 2020

As such, the company has implemented measures to help ensure the continuity of its clinical trials and programs, while maintaining the safety of patients, clinicians and employees.

Key Points: 
  • As such, the company has implemented measures to help ensure the continuity of its clinical trials and programs, while maintaining the safety of patients, clinicians and employees.
  • The COVID-19 task force will closely monitor all clinical trials and collect data relevant to the patients study treatments and schedules.
  • If patients have questions about their clinical trial, they should reach out to the clinical trial coordinator at their medical center.
  • The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements.